Diabetes Drug Summary
|
Drug | Mechanism | Benefits | Side Effects | Rating |
Metformin, Metformin ER | Keeps liver from dumping glucose. Makes muscles take up glucose. | Reduces
insulin resistance and lowers triglycerides. Appears to protect
against breast cancer and lower risk of other cancers. Protects heart
during heart attack and may prevent heart attack | Gas,
abdominal pain, diarrhea. May cause Vitamin-B12 deficiency with long
use. Fewer side effects with ER/XR extended release form. Fear it causes
lactic acidosis is not supported by high quality research. | +++++ |
Avandia, (rosiglitazone) Avandamet (Avandamet is Avandia combined with metformin) | Affects PPAR-gamma receptor Grows new fat cells that take up glucose. | Reduces insulin resistance. | 66%
more heart attacks. Causes water retention. Causes weight gain. Causes
heart failure. Causes osteoporosis. Causes macular edema | ----- |
Actos (pioglitazone) | Same as Avandia | Reduces insulin resistance | From
Prescribing Information: "In post marketing experience with ACTOS, cases
of congestive heart failure have been reported in patients both with
and without previously known heart disease....In post marketing
experience with ACTOS, reports of hepatitis and of hepatic enzyme
elevations to 3 or more times the upper limit of normal have been
received. Very rarely, these reports have involved hepatic failure with
and without fatal outcome"Macular edema. Weight gain. Ovulation in
premenopausal women. Raises LDL. | ----- |
Precose (acarbose) | Blocks alpha glucosidase enzyme used to break down starches and complex sugars | Slows the digestion of carbs so that second phase insulin can deal with them | Gas | +++ |
Diamicron (gliclazide)--not sold in U.S. | Sulfonylurea.
Stimulates beta cell to secrete insulin for 8 - 12 hours whether or not
glucose is present in bloodstream. The only sulfonylurea that does nto
increase the risk of heart attack death | Raises insulin level | Can
cause hypos. Causes hunger and weight gain May cause reversible beta
cell burnout with prolonged use. Least heart attack risk of this class
of drugs. | + |
Amaryl (glimepiride), Glyburide, (Glucovance is glyburide with added metformin)
Glucatrol, Diabeta (glipizide) | Sulfonylurea. Stimulates beta cell to secrete insulin for 8 - 12 hours whether or not glucose is present in bloodstream | Raises insulin level | Stimulate receptors on heart tissue leading to higher rate of heart attacks | --- |
Starlix (natalinide) | Meglitinide. Stimulates beta cell to secrete insulin for 1-3 hours whether or not glucose is present in bloodstream | Raises insulin level for a short time. Inhibits DPP-4 briefly | Can cause hypos. Causes weight gain, upper respiratory infection, back pain, flu symptoms, dizziness, joint problems. | - |
Prandin (repaglinide) | Meglitinide. Stimulates beta cell to secrete insulin for 1-3 hours whether or not glucose is present in bloodstream | Stimulates insulin secretionl for 1-3 hours. The most heart-safe insulin stimulating drug available in the U.S.. | Can
cause hypos. Same dose much more powerful when combined with metformin.
Causes weight gain. Changes concentration of many other drugs including
birth control pills in the bloodstream. May cause upper respiratory
infection, back pain, flu symptoms, dizziness, joint problems. | -- |
Byetta (exenatide) Bydureon is a long-lasting version of Byetta | Synthetic GLP-1 | Slows
stomach emptying, which can lead to weight loss. Stimulates insulin
secretion in intact beta cells. Very effective for 1/3 of those who take
it, occasionally producing dramatic weight loss. | Vomiting.
Nausea. Chills. Headache. Weakness. Blood pressure fluctuations. Tooth
pain. Constipation. Nasal congestion. Very rarely, is associated with
pancreatitis. | ++ |
Victoza | Synthetic GLP-1 | Slows
stomach emptying, which can lead to weight loss. Stimulates insulin
secretion in intact beta cells. Less effective than Byetta but causes
far more side effects than Byetta. | Label contains
Black Box warning "Liraglutide injection may increase the risk that you
will develop tumors of the thyroid gland, including medullary thyroid
carcinoma (MTC; a type of thyroid cancer), which may cause death if it
is not treated at an early stage." May cause renal [kidney] impairment.
Study shows it causes more serious rashes than Byetta. Vomiting. Nausea.
Chills. Headache. Weakness. Blood pressure fluctuations. Tooth pain.
Constipation. Nasal congestion. Very rarely, is associated with
pancreatitis. | ++ |
Januvia (sitagliptin)
Janumet is Januvia combined with metformin | Inhibits
the DPP-4 protease allowing GLP-1 and GIP levels to rise and stimulate
insulin secretion and decrease glucagon production. DPP-4 is also a
tumor suppressor gene, so inhibition of DPP-4 may promote cancers. | Stimulates insulin secretion in intact beta cells. | Label
warns it may cause pancreatitis, acute renal (kidney) failure, and
severe allergic reactions including severe skin rashes. Cold symptoms,
inflamed sinuses, raised blood pressure,constipation. Elevated leucocyte
count. DPP-4 inhibition has been called "trigger for prostate cancer",
also associated with metastasis in ovarian and lung cancers and
melanoma. | -- |
Onglyza
(saxagliptin), Trajenta (linagliptin) Kombiglyze is Onglyza combined
with metformin. Jentadueto is Trajenta and Metformin | Inhibits
the DPP-4 protease allowing GLP-1 and GIP levels to rise and stimulate
insulin secretion and decrease glucagon production. DPP-4 is also a
tumor suppressor gene, so inhibition of DPP-4 may promote cancers.. | Stimulates insulin secretion in intact beta cells. | Label
warns these drugs may cause acute pancreatitis, severe allergic
reactions. Commonly causes cold symptoms, inflamed sinuses, raised
blood pressure,constipation. Lowers lymphocytes, sometimes dangerously. Concentration
rises with grapefruit juice, ketoconazole, erythromycin, and verapamil.
Raises peak concentrations of sulfonylureas, Actos and Avandia causing
hypos. DPP-4 inhibition has been called "trigger for prostate
cancer", also associated with metastasis in ovarian and lung cancers and
melanoma. | -- |
No comments:
Post a Comment